Meet us at AASLD, booth \#1861 to learn how our deep expertise in imaging-based hepatic biomarkers and global operational support help sponsors optimise trial design and accelerate the delivery of MASH treatments to pati...

A cross-functional challenge JCA introduces a common scientific assessment, but evidence expectations can span different populations, comparators, outcomes and national standards of care. A joined-up, cross-functional st...

Product arrival isn’t the same as treatment readiness. Before a patient can dose in a cell or gene therapy study, teams may need to verify identity, custody, release, product condition, timing and site readiness. If one ...

We're looking forward to seeing you at #OCTDACH tomorrow in Basel. Join the ICON team at booth \#6 and discover how we're helping sponsors navigate complexity, accelerate trial delivery, and bring therapies to patients ...

As competition intensifies, biosimilar developers must look beyond traditional approaches and prepare for more complex molecules, tighter timelines and global market dynamics. Forward-thinking strategies can help program...

The biosimilar landscape is changing. Recent regulatory developments could streamline development, accelerate market entry and intensify competition for off-patent biologics. In a new PM360 Think Tank article, six indust...

Advancing an asset towards human studies but not there yet? Stop by ICON Booth \#1861 and speak with one of our drug development scientists. Learn how we approach development and how our nonclinical, CMC, and regulatory ...

When a data issue is closed, how do you know it’s really been resolved? Join Shabeeb Kannattikuni at the PHUSE Single Day Event in North Carolina, where he’ll share a SAS-based solution to checking data issue resolution...

Successful obesity trials depend on reaching and engaging the right patients. At #ObesityWeek, visit ICON at booth \#212 to explore recruitment expertise and retention-focused strategies designed to support long-term eng...

Congress participation decisions made easier. Meetings are expensive, arrangements are time consuming. With 50+ data fields to compare details, PubsHub Journals & Congresses makes your decision making faster and easier. ...

The 2028 milestone Orphan medicinal products will come under JCA rules in January 2028, with all remaining medicines following by 2030. For sponsors already in phase 2, the decisions made today could shape future Europea...

The questions facing healthcare decision-makers are becoming increasingly complex. How do we generate better evidence? Measure outcomes more effectively? Apply AI responsibly? Ensure patient perspectives are reflected? J...